Do analysts prefer RFL or SPRY?

ARS Pharmaceuticals has a consensus price target of $26.40, indicating a potential upside of 542.34%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ARS Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is RFL or SPRY more profitable?

ARS Pharmaceuticals has a net margin of -184.24% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat ARS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% ARS Pharmaceuticals -184.24% -256.67% -69.63%

Does the media prefer RFL or SPRY?

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than Rafael. MarketBeat recorded 16 mentions for ARS Pharmaceuticals and 1 mentions for Rafael. Rafael's average media sentiment score of 0.00 beat ARS Pharmaceuticals' score of -0.07 indicating that Rafael is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RFL or FENC?

Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 60.08%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer RFL or FENC?

In the previous week, Rafael and Rafael both had 1 articles in the media. Rafael's average media sentiment score of 0.00 equaled Adherex Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RFL or BIOA?

BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 353.74%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher earnings and valuation, RFL or BIOA?

Rafael has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael $920K 116.27 -$30.52M -$0.68 N/A BioAge Labs $8.99M 41.15 -$80.61M -$2.38 N/A

Is RFL or BIOA more profitable?

BioAge Labs has a net margin of -912.26% compared to Rafael's net margin of -3,321.74%. BioAge Labs' return on equity of -28.99% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% BioAge Labs -912.26% -28.99% -27.09%

Does the media prefer RFL or BIOA?

In the previous week, BioAge Labs had 3 more articles in the media than Rafael. MarketBeat recorded 4 mentions for BioAge Labs and 1 mentions for Rafael. BioAge Labs' average media sentiment score of 0.26 beat Rafael's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RFL or ENTA?

Enanta Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 72.13%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend EYPT or RFL?

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, suggesting a potential upside of 567.53%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyepoint Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor EYPT or RFL?

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than Rafael. MarketBeat recorded 7 mentions for Eyepoint Pharmaceuticals and 1 mentions for Rafael. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rafael 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rafael (RFL) Competitors

$2.06 0.00 (-0.15%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$2.06 0.00 (-0.10%)

As of 09/18/2026 07:30 PM Eastern

Compare

RFL vs. SPRY, FENC, BIOA, ENTA, and EYPT

Should you buy Rafael stock or one of its competitors? Rafael's main competitors and comparable companies include ARS Pharmaceuticals (SPRY), Adherex Technologies (FENC), BioAge Labs (BIOA), Enanta Pharmaceuticals (ENTA), and Eyepoint Pharmaceuticals (EYPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Rafael compare to ARS Pharmaceuticals?

Rafael (NYSE:RFL) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

ARS Pharmaceuticals has a consensus price target of $26.40, indicating a potential upside of 542.34%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

11.3% of Rafael shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 32.9% of Rafael shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rafael has higher earnings, but lower revenue than ARS Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A
ARS Pharmaceuticals	$84.28M	4.85	-$171.30M	-$2.18	N/A

Rafael has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than Rafael. MarketBeat recorded 16 mentions for ARS Pharmaceuticals and 1 mentions for Rafael. Rafael's average media sentiment score of 0.00 beat ARS Pharmaceuticals' score of -0.07 indicating that Rafael is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals has a net margin of -184.24% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Summary

ARS Pharmaceuticals beats Rafael on 10 of the 16 factors compared between the two stocks.

How does Rafael compare to Adherex Technologies?

Rafael (NYSE:RFL) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Adherex Technologies has higher revenue and earnings than Rafael. Adherex Technologies is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A
Adherex Technologies	$44.64M	8.34	-$9.74M	-$0.13	N/A

11.3% of Rafael shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Rafael and Rafael both had 1 articles in the media. Rafael's average media sentiment score of 0.00 equaled Adherex Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 60.08%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adherex Technologies has a net margin of -6.09% compared to Rafael's net margin of -3,321.74%. Adherex Technologies' return on equity of -5.71% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Rafael has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Summary

Adherex Technologies beats Rafael on 11 of the 14 factors compared between the two stocks.

How does Rafael compare to BioAge Labs?

Rafael (NYSE:RFL) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

11.3% of Rafael shares are owned by institutional investors. 32.9% of Rafael shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 353.74%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, BioAge Labs had 3 more articles in the media than Rafael. MarketBeat recorded 4 mentions for BioAge Labs and 1 mentions for Rafael. BioAge Labs' average media sentiment score of 0.26 beat Rafael's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rafael has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A
BioAge Labs	$8.99M	41.15	-$80.61M	-$2.38	N/A

Rafael has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

BioAge Labs has a net margin of -912.26% compared to Rafael's net margin of -3,321.74%. BioAge Labs' return on equity of -28.99% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
BioAge Labs	-912.26%	-28.99%	-27.09%

Summary

BioAge Labs beats Rafael on 10 of the 16 factors compared between the two stocks.

How does Rafael compare to Enanta Pharmaceuticals?

Rafael (NYSE:RFL) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Enanta Pharmaceuticals has a net margin of -96.89% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

11.3% of Rafael shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 32.9% of Rafael shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rafael has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Enanta Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 72.13%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Rafael has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A
Enanta Pharmaceuticals	$65.26M	5.44	-$81.89M	-$2.41	N/A

In the previous week, Rafael had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 1 mentions for Rafael and 0 mentions for Enanta Pharmaceuticals. Rafael's average media sentiment score of 0.00 equaled Enanta Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Rafael	Neutral
Enanta Pharmaceuticals	Neutral

Summary

Enanta Pharmaceuticals beats Rafael on 8 of the 15 factors compared between the two stocks.

How does Rafael compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, suggesting a potential upside of 567.53%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rafael has a net margin of -3,321.74% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Rafael's return on equity of -41.27% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Rafael	-3,321.74%	-41.27%	-35.32%

Rafael has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	10.58	-$231.96M	-$3.74	N/A
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A

Eyepoint Pharmaceuticals has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Rafael has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than Rafael. MarketBeat recorded 7 mentions for Eyepoint Pharmaceuticals and 1 mentions for Rafael. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eyepoint Pharmaceuticals beats Rafael on 8 of the 15 factors compared between the two stocks.

Get Rafael News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RFL vs. The Competition

Export

Metric	Rafael	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$107.12M	$12.45B	$7.24B	$23.16B
Dividend Yield	N/A	2.63%	2.57%	3.59%
P/E Ratio	-3.03	797.25	275.79	28.21
Price / Sales	116.27	950.97	695.58	19.15
Price / Cash	N/A	88.44	77.42	34.53
Price / Book	1.08	10.53	10.46	4.67
Net Income	-$30.52M	$2.82B	$3.49B	$1.07B
7 Day Performance	-10.76%	1.69%	0.59%	-1.64%
1 Month Performance	12.40%	0.83%	-2.01%	-4.25%
1 Year Performance	44.86%	3.90%	18.09%	8.32%

Rafael Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RFL Rafael	0.125 of 5 stars	$2.06 -0.1%	N/A	+29.4%	$107.12M	$920K	N/A	23	Short Interest Increase High Trading Volume
SPRY ARS Pharmaceuticals	1.6961 of 5 stars	$4.13 -0.6%	$26.40 +540.0%	-58.6%	$409.22M	$116.93M	N/A	200
FENC Adherex Technologies	3.6369 of 5 stars	$10.66 -1.2%	$17.00 +59.5%	+18.9%	$373.63M	$44.64M	N/A	35
BIOA BioAge Labs	2.22 of 5 stars	$7.98 -1.4%	$36.57 +358.3%	+54.4%	$364.68M	$8.99M	N/A	62
ENTA Enanta Pharmaceuticals	1.6914 of 5 stars	$12.40 -0.9%	$21.00 +69.3%	+55.6%	$359.31M	$65.32M	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RFL) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rafael (RFL) Competitors

RFL vs. SPRY, FENC, BIOA, ENTA, and EYPT

How does Rafael compare to ARS Pharmaceuticals?

Summary

How does Rafael compare to Adherex Technologies?

Summary

How does Rafael compare to BioAge Labs?

Summary

How does Rafael compare to Enanta Pharmaceuticals?

Summary

How does Rafael compare to Eyepoint Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rafael (RFL) Competitors

RFL vs. SPRY, FENC, BIOA, ENTA, and EYPT

How does Rafael compare to ARS Pharmaceuticals?

Do analysts prefer RFL or SPRY?

Do insiders & institutionals have more ownership in RFL or SPRY?

Which has stronger earnings & valuation, RFL or SPRY?

Which has more risk and volatility, RFL or SPRY?

Does the media prefer RFL or SPRY?

Is RFL or SPRY more profitable?

Summary

How does Rafael compare to Adherex Technologies?

Which has better valuation & earnings, RFL or FENC?

Do insiders and institutionals have more ownership in RFL or FENC?

Does the media prefer RFL or FENC?

Do analysts prefer RFL or FENC?

Is RFL or FENC more profitable?

Which has more volatility and risk, RFL or FENC?

Summary

How does Rafael compare to BioAge Labs?

Do insiders & institutionals have more ownership in RFL or BIOA?

Do analysts rate RFL or BIOA?

Does the media prefer RFL or BIOA?

Which has higher earnings and valuation, RFL or BIOA?

Which has more risk & volatility, RFL or BIOA?

Is RFL or BIOA more profitable?

Summary

How does Rafael compare to Enanta Pharmaceuticals?

Is RFL or ENTA more profitable?

Do institutionals and insiders believe in RFL or ENTA?

Which has more risk & volatility, RFL or ENTA?

Do analysts recommend RFL or ENTA?

Which has preferable valuation & earnings, RFL or ENTA?

Does the media prefer RFL or ENTA?

Summary

How does Rafael compare to Eyepoint Pharmaceuticals?

Do analysts recommend EYPT or RFL?

Is EYPT or RFL more profitable?

Which has better valuation and earnings, EYPT or RFL?

Which has more volatility & risk, EYPT or RFL?

Do insiders and institutionals have more ownership in EYPT or RFL?

Does the media favor EYPT or RFL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools